AstraZeneca Pharma India Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Sanjeev Panchal
Chief executive officer
₹21.1m
Total compensation
| CEO salary percentage | 24.2% |
| CEO tenure | 1.3yrs |
| CEO ownership | n/a |
| Management average tenure | 1.1yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹21m | ₹5m | ₹993m |
Compensation vs Market: Sanjeev's total compensation ($USD253.45K) is below average for companies of similar size in the Indian market ($USD433.15K).
Compensation vs Earnings: Insufficient data to compare Sanjeev's compensation with company performance.
CEO
Sanjeev Panchal (46 yo)
1.3yrs
Tenure
₹21,149,014
Compensation
Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, Country President & Director | 1.3yrs | ₹21.15m | no data | |
| Whole-Time Director & CFO | less than a year | no data | no data | |
| Legal Counsel | 7.3yrs | ₹3.73m | no data | |
| Company Secretary & Compliance Officer | 1.8yrs | no data | no data | |
| Vice President of Human Resources | no data | ₹12.28m | no data | |
| Interim Business Unit Head of Oncology & Director of Commercial Excellence | less than a year | no data | no data | |
| Head of Oncology Business Unit | less than a year | no data | no data | |
| Finance Controller | no data | no data | no data |
1.1yrs
Average Tenure
Experienced Management: ASTRAZEN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, Country President & Director | 1.3yrs | ₹21.15m | no data | |
| Whole-Time Director & CFO | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.4yrs | ₹1.20m | no data | |
| Independent Chairman of the Board | 11.4yrs | ₹1.40m | no data | |
| Additional Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.4yrs | ₹1.30m | no data | |
| Additional Non-Executive Director | 4yrs | no data | no data | |
| Non-Executive Director | less than a year | no data | no data |
1.9yrs
Average Tenure
51yo
Average Age
Experienced Board: ASTRAZEN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.